deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 certainty unassessablestatistically conclusive-22%